Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy.

Oral treprostinil, approved for the treatment of pulmonary arterial hypertension, remains an attractive option in combination with other medications to delay disease progression and improve exercise capacity. However, patients are often challenged with the ability to overcome adverse effects as outpatients and reach effective doses in a timely manner. We describe a case of a 47-year-old female on oral treprostinil who presented to the clinic with worsening symptoms of disease, necessitating higher dosing.

Immunohistochemical analysis of growth factors in platelet-rich fibrin membranes.

The use of autogenous materials to promote tissue regeneration has guided the direction of modern dentistry, and platelet-rich fibrin (PRF) is a promising biomaterial for tissue engineering. This in vitro immunohistochemical study aimed to analyze the presence of factors of endothelial growth and cell differentiation in PRF membranes by using the CD31 (endothelial cells) and CD163 (monocytes) markers. Five men and 5 women, aged between 25 and 60 years and without systemic health problems, were enrolled in the study.